#PostConvo #IBDPoll 1️⃣ #MondayNightIBD
🏆🆓#CME👉🏼 http://bit.ly/3DZPnHV

#ORAL Surveillance study: Risk of major adverse cardiovascular event (MACE) was ⬆️ with #Tofacitinib vs TNFi at median of 4 yrs f/up in pts> age 50 + at least 1 CV risk factors in which chronic disease:

MondayNightIBD | UC Refractory to TNFi - Considerations for Next Therapies | November 7, 2022 - Aline Charabaty, MD, AGAF, FACG *Post-test*

Take this survey powered by surveymonkey.com. Create your own surveys for free.

JoiningUnrelatedDots (@Mareeswj)

1/1/21 update: drugs for #Covid_19 all phases: Famotidine Indomethacin Spironolactone Ivermectin Vitamin D Vitamin C Mild: Bromhexine Omeprazole/Nitazoxanide Fluvoxamine Moderate: Interferon Colchicine Ciclesonide Severe: Cyproheptadine Dexamethasone